# **Corporate Action Notice**

October 2, 2015

## **Ratio Change and Stock Distribution**

Nomura Research Institute Ltd

ADR CUSIP: 65538C107 / ADR ISIN: US65538C1071

**ADR Ticker Symbol: NRILY** 

Ratio: (ADS: Underlying Shares): 1:2

Please be advised that Nomura Research Institute Ltd has announced an 11 for 10 stock split on its ordinary shares in the local market effective October 1, 2015. As a result, BNY Mellon will change the ratio on the Nomura Research Institute Ltd American Depositary Receipt ("ADR") program. The ratio change will occur simultaneously with a 780% American Depositary Share ("ADS") distribution (7.8 additional ADSs for every 1 ADS held).

Please note: A ratio change may impact the fees payable by ADR investors.

BNY Mellon's books were closed from the close of business September 29, 2015 and will reopen on October 19, 2015 for Issuance and Cancellation transactions.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

ADR Record Date: October 9, 2015
ADR Payable Date: October 13, 2015

DR Distribution Rate: 780%
Old Ratio: 1 ADS: 2 Ordinary shares
New Ratio: 4 ADSs: 1 Ordinary Share

Issuance Fee: \$0.00 per ADS

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

### **NEW YORK**

Ravi Davis Richard J Maehr + 1 212 815 2267 adrdesk@bnymellon.com

### **LONDON**

Jacek Jankowski Vice President + 44 207 163 7427 jacek.jankowski@bnymellon.com

### **HONG KONG**

Herston Powers Vice President + 852 2 840 9868

herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

